Health Technology
Nichi-Iko Pharmaceutical Co., Ltd.
In the news
- Japan's generic drugmakers have a China dependency problem Nov 5, 2019
- China extends drug patents to 25 years May 16, 2018
- Takeda-Shire deal shows it's US or bust for Japanese drugmakers May 10, 2018
- Nichi-Iko to sell generics in Philippines, Singapore Sep 2, 2017
- Teva Takeda Pharma shooting for $916m in sales in 2017 Apr 22, 2017 See more articles on Nichi-Iko Pharmaceutical Co., Ltd.
Business Summary
Nichi-Iko Pharmaceutical Co., Ltd. engages in the manufacturing, sales, distribution, export, import and related activities for various types of pharmaceutical products. The company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems and others. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.
Financial Highlights
| Mar 2019 | JPY | USD |
| Revenue | 166,592M | 1,502.25M |
| Gross Profit | 33,158M | 299.00M |
| Operating income | 7,221M | 65.11M |
| Income before tax | 8,903M | 80.28M |
| Net income | 6,864M | 61.89M |
| EBITDA | 16,987M | 153.18M |
| Diluted EPS | 114.03 | 1.02 |
| Dividends Per Share | 30 | 0.27 |
| Total Assets | 306,838M | 2,772.17M |
| Total liabilities | 190,511M | 1,721.19M |
| Total equity | 116,323M | 1,050.93M |
| Operating cash flow | 23,811M | 214.71M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 127,021M | 143,513M | 149,263M | 164,717M | 166,592M |
| Gross Profit | 46,876M | 53,313M | 37,611M | 40,803M | 33,158M |
| Operating income | 9,619M | 12,910M | 10,026M | 13,200M | 7,221M |
| Income before tax | 9,488M | 15,359M | 5,963M | 9,067M | 8,903M |
| Net income | 6,592M | 11,031M | 4,796M | 8,069M | 6,864M |
| EBITDA | 20,265M | 24,200M | 17,091M | 22,179M | 16,987M |
| Diluted EPS | 110.13 | 184.01 | 84.08 | 142.92 | 114.03 |
| Dividends Per Share | 26.60 | 30 | 30 | 30 | 30 |
| Total Assets | 139,834M | 161,128M | 268,900M | 278,364M | 306,838M |
| Total liabilities | 65,347M | 78,531M | 185,725M | 190,819M | 190,511M |
| Total equity | 74,487M | 82,597M | 83,171M | 87,542M | 116,323M |
| Operating cash flow | 21,179M | 7,097M | -4,076M | 18,925M | 23,811M |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 1,156.24M | 1,195.10M | 1,378.39M | 1,486.18M | 1,502.25M |
| Gross Profit | 426.70M | 443.96M | 347.32M | 368.15M | 299.00M |
| Operating income | 87.55M | 107.50M | 92.58M | 119.09M | 65.11M |
| Income before tax | 86.36M | 127.90M | 55.06M | 81.80M | 80.28M |
| Net income | 60.00M | 91.86M | 44.28M | 72.80M | 61.89M |
| EBITDA | 184.46M | 201.52M | 157.82M | 200.11M | 153.18M |
| Diluted EPS | 1.00 | 1.53 | 0.77 | 1.28 | 1.02 |
| Dividends Per Share | 0.24 | 0.24 | 0.27 | 0.27 | 0.27 |
| Total Assets | 1,166.01M | 1,433.58M | 2,413.17M | 2,617.43M | 2,772.17M |
| Total liabilities | 544.89M | 698.70M | 1,666.74M | 1,794.25M | 1,721.19M |
| Total equity | 621.11M | 734.88M | 746.39M | 823.14M | 1,050.93M |
| Operating cash flow | 192.78M | 59.10M | -37.64M | 170.75M | 214.71M |
Valuation Measures
| Mar 2019 | |
| PER | 12.71 |
| ROA | 2.34% |
| ROE | 6.73% |
| Operating margin | 4.33% |
| Profit margin | 4.12% |
Key executives
- President & Representative Director: Yuichi Tamura
- Finance Manager: Naoyuki Okada
- Head-Compliance Management & Guidance: Yasutomo Sai
- Director, VP, Head-CSR, ESG & Business Creation: Kenji Akane
- Executive Officer & Personnel Manager: Keiichi Arakawa
Shareholders
- TAMURA YUICHI /NICHI IKO PHARMACEUTICAL/ (12.9%)
- Asset Management One Co., Ltd. (5.0%)
- Hokuhoku Financial Group, Inc. (4.3%)
- The Vanguard Group, Inc. (2.0%)
- Nipro Corp. (2.0%)
- Goldman Sachs Asset Management LP (1.8%)
- Nomura Asset Management Co., Ltd. (1.8%)
- Sumitomo Mitsui DS Asset Management Co., Ltd. (1.8%)
- Nichi-Iko Pharmaceutical Co., Ltd. (1.4%)
- Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.3%)
Contact Details
- Website:http://www.nichiiko.co.jp
- Phone: +81.76.432.2121
Related Companies
- Nichi-Iko Pharma Tech Co., Ltd.
- Elmed Co. Ltd.
- Nichi Iko Pharmaceutical Trust
- Nichi-Iko Pharmaceutical Employee Incentive Plan
- Nichiiko Pharma KK
- Nichiiko Osaka KK
- Yakuhan Pharmaceutical Co., Ltd.
- Sagent Pharmaceuticals, Inc.
- Kobayashi Pharmaceutical Industries Co. Ltd.
- Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
- Oriental Pharmaceutical Co., Ltd.
- Teikoku Medix Co., Ltd.
- Japan Galen, Inc.
- Maruko Pharmaceutical Co. Ltd.
- Nichiiko Pharmaceutical Employee Stock Pwnership Plan
Competitors
- Dr. Reddy's Laboratories Ltd.
- Hikma Pharmaceuticals Plc
- Five Prime Therapeutics, Inc.
- Amphastar Pharmaceuticals Inc
- Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 30 Mar, 2020